RU2011143520A - Способы и композиции для лечения злокачественных опухолей - Google Patents

Способы и композиции для лечения злокачественных опухолей Download PDF

Info

Publication number
RU2011143520A
RU2011143520A RU2011143520/15A RU2011143520A RU2011143520A RU 2011143520 A RU2011143520 A RU 2011143520A RU 2011143520/15 A RU2011143520/15 A RU 2011143520/15A RU 2011143520 A RU2011143520 A RU 2011143520A RU 2011143520 A RU2011143520 A RU 2011143520A
Authority
RU
Russia
Prior art keywords
composition according
composition
inhibitor
compound
acid ceramidase
Prior art date
Application number
RU2011143520/15A
Other languages
English (en)
Russian (ru)
Inventor
ДЕ МОЛИНА Ана РАМИРЕС
ОРОС Лурдес ГАРСИЯ
САНХУАН Хуан Карлос ЛАКАЛЬ
Original Assignee
Траслэшионал Кэнсэр Драгз Фарма, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Траслэшионал Кэнсэр Драгз Фарма, С.Л. filed Critical Траслэшионал Кэнсэр Драгз Фарма, С.Л.
Publication of RU2011143520A publication Critical patent/RU2011143520A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
RU2011143520/15A 2008-09-17 2009-09-17 Способы и композиции для лечения злокачественных опухолей RU2011143520A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380270.2 2008-09-17
EP08380270 2008-09-17
PCT/EP2009/062078 WO2010031825A2 (en) 2008-09-17 2009-09-17 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
RU2011143520A true RU2011143520A (ru) 2013-05-10

Family

ID=40364454

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011143520/15A RU2011143520A (ru) 2008-09-17 2009-09-17 Способы и композиции для лечения злокачественных опухолей

Country Status (15)

Country Link
US (4) US20100068302A1 (https=)
EP (1) EP2340042B1 (https=)
JP (1) JP2012502954A (https=)
KR (1) KR20110067041A (https=)
CN (1) CN102215872B (https=)
AU (1) AU2009294618A1 (https=)
BR (1) BRPI0919238A2 (https=)
CA (1) CA2737551A1 (https=)
DK (1) DK2340042T3 (https=)
ES (1) ES2527361T3 (https=)
MX (1) MX2011002956A (https=)
PL (1) PL2340042T3 (https=)
PT (1) PT2340042E (https=)
RU (1) RU2011143520A (https=)
WO (1) WO2010031825A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
WO2012051415A2 (en) * 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
JP2014527397A (ja) 2011-06-20 2014-10-16 トラスラショナル、キャンサー、ドラッグス、ファーマ、ソシエダッド、リミターダＴｒａｓｌａｔｉｏｎａｌ Ｃａｎｃｅｒ Ｄｒｕｇｓ Ｐｈａｒｍａ， Ｓ．Ｌ． 癌患者の化学療法に対する臨床応答を予測する方法
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
ES2897825T3 (es) * 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US11813338B2 (en) 2013-03-12 2023-11-14 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
KR101537030B1 (ko) * 2013-08-23 2015-07-16 (주)바이오디펜스 천적동물의 눈을 포함한 홀로그램을 이용한 농작물 보호방법 및 그 보호기구
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
US12458659B2 (en) * 2019-02-06 2025-11-04 The Regents Of The University Of California Methods for treating macrophage-mediated diseases, and methods of identifying agents useful therefore
US20220362254A1 (en) * 2019-08-22 2022-11-17 Thomas Jefferson University Methods for reprogramming cancer cells
JP7594358B2 (ja) * 2019-11-29 2024-12-04 株式会社ダイセル エクソソーム産生促進剤
CN114644626A (zh) * 2020-12-18 2022-06-21 南京施江医药科技有限公司 一种苯环类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
ES2117950B1 (es) * 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
ES2237332B1 (es) * 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
RU2006146612A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
WO2006108905A1 (es) * 2005-04-13 2006-10-19 Consejo Superior De Investigaciones Científicas Método in vitro para identificar compuestos para terapia del cáncer
ES2277568B1 (es) * 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.

Also Published As

Publication number Publication date
PL2340042T3 (pl) 2015-01-30
WO2010031825A2 (en) 2010-03-25
CN102215872A (zh) 2011-10-12
MX2011002956A (es) 2011-08-03
EP2340042A2 (en) 2011-07-06
EP2340042B1 (en) 2014-07-23
CA2737551A1 (en) 2010-03-25
US20150297576A1 (en) 2015-10-22
AU2009294618A1 (en) 2010-03-25
US20110256241A1 (en) 2011-10-20
ES2527361T3 (es) 2015-01-22
PT2340042E (pt) 2014-11-27
BRPI0919238A2 (pt) 2019-09-24
AU2009294618A2 (en) 2011-04-14
US20100068302A1 (en) 2010-03-18
HK1159498A1 (en) 2012-08-03
CN102215872B (zh) 2015-06-10
WO2010031825A3 (en) 2010-08-19
JP2012502954A (ja) 2012-02-02
KR20110067041A (ko) 2011-06-20
DK2340042T3 (da) 2014-10-27
US20120040021A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
RU2011143520A (ru) Способы и композиции для лечения злокачественных опухолей
JP2012502954A5 (https=)
US20220378787A1 (en) Dosing of kras inhibitor for treatment of cancers
US20240082251A1 (en) Dosing regimen of kras g12c inhibitor
Lee et al. Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
Grünewald et al. Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
CN107849022A (zh) 取代的喹唑啉化合物和其使用方法
CN110507654A (zh) 有酪氨酸激酶抑制剂的组合产品和其应用
CN107207510B (zh) 联合疗法
Song et al. Targeting drug‐tolerant cells: a promising strategy for overcoming acquired drug resistance in cancer cells
ES2702038T3 (es) Métodos de tratamiento de fibrosis y cánceres
RU2008138534A (ru) Фармацевтическая комбинация для лечения и/или хемосенсебилизации опухолей, устойчивых к противораковым средствам
Wei et al. Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations
Pectasides et al. Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma
Chen et al. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells
US12329755B2 (en) Bromodomain inhibitors to target therapy-resistant cancer
Shi et al. Treatment for triple-negative breast cancer
AR049135A1 (es) Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib
RU2809720C2 (ru) Применение производного инденофлуорена для ингибирования и/или элиминации опухолевых клеток
Dutcher High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
Zhu et al. Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer
Lai et al. Discovery of selective PARP1/CDK6 dual target inhibitors modulating Wnt signaling pathway for the treatment of TNBC
Fu et al. Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
Papadopoulou et al. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150622